A tale of two time periods: Ovarian cancer trends in Ontario

Current Oncology

Volumn 14, Issue 2, 2007, Pages 57-60

  Elit, Laurie ^a,e   Bondy, Susan J ^b,c   Chen, Zhongliang ^c   Paszat, Lawrence ^c,d  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

Outcomes; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

ABDOMINAL SURGERY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANADA; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; OVARY CANCER; PROGNOSIS; SURVIVAL RATE;

EID: 44949198348     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.2007.106     Document Type: Article

References (12)

1. McGuire WP, Hoskin WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
2. Elit L, Chartier C, Oza A, Hirte H, Levine M, Paszat L. Outcomes for systemic therapy in ovarian cancer. Gynecol Oncol 2006;103:554-8.
3. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40:373-83.
4. National Cancer Institute of Canada, Statistics Canada, Provincial/ Territorial Cancer Registries, and Health and Welfare Canada. Canadian Cancer Statistics 1996. Toronto: National Cancer Institute of Canada; 1996: 247.
5. Statistics Canada, Health and Welfare Canada, and National Cancer Institute of Canada. Canadian Cancer Statistics 2001. Toronto: National Cancer Institute of Canada; 2001: 26.
6. Kjaerbye-Thygesen A, Huusom LD, Frederiksen K, Kjaer SK. Trends in the incidence and mortality of ovarian cancer in Denmark 1978-2002. Comparison with other Nordic countries. Acta Obstet Gynecol Scand 2005;84:1006-12.
7. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995;45:8-30.
8. Bray F, Loos AH, Tognazzo S, La Vecchia C. Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953-2000. Int J Cancer 2005;113:977-90.
9. Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005;97:1407-27.
10. Elit L, Bondy S, Chen Z, Law C, Paszat L. The quality of operative reports for women with ovarian cancer. J Obstet Gynecol Can 2006;28:892-7.
11. Piccart MJ, Bertelsen K, James K, et al. Randomized Inter-group trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708.
12. Carey M, Covens A, Bryson P, et al. First-line chemotherapy for postoperative patients with stage II, III, or IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer [practice guideline report 4-1]. Toronto: Program in Evidence-Based Care, Cancer Care Ontario; 2001.